

***This report has been issued for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of third parties regarding revenues, earnings and business developments. Such estimates and forecasts cannot be independently verified by reason of the subjective character. CPH Group AG gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.***

***This report is not a prospectus within the meaning of art. 652a CO or art. 27 et seq. of the SIX Listing Rules. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives and no investment decision should be based on this report. This report speaks as of its date. Neither CPH Group AG nor Dynamics Group AG assume any responsibility to up-date the report.***

# CPH Group AG

Switzerland | Industrial Goods & Services

## FY25 Results update


23 February 2026

### Company Data

Price:	CHF 64.00
Market Cap:	CHF 386.3mn
Free Float:	61.7%
No. of shares:	6.0mn
Avg. traded volume (30 day):	1,495
Bloomberg:	CPHN SW
Reuters:	CPHN-EB
ISIN:	CH0001624714

Source: SIX Swiss Exchange and Bloomberg

### Share Price Development



Source: Bloomberg

### Key Financial Data

	2024	2025	2026E	2027E
Sales	323.3	334.1	349.0	365.2
EBITDA %	16.6%	15.0%	15.5%	16.0%
EBIT %	12.1%	9.8%	10.4%	11.0%
Net Margin %	10.7%	7.0%	7.7%	8.3%
Basic EPS	5.7	3.9	4.5	5.0
Diluted EPS	5.7	3.9	4.5	5.0
DPS	2.0	2.0	2.5	2.5
Equity Ratio %	63.0%	55.3%	58.0%	61.2%
Capex	(18.5)	(17.7)	(16.2)	(17.2)
P/Sales	1.2x	1.1x	1.1x	1.1x
P/E	11.5x	16.4x	14.3x	12.8x
EV/EBITDA	7.6x	8.2x	7.6x	7.0x

Source: Research Dynamics, Company data

### Next Events

AGM, Lucerne	17 Mar 2026
Publication half-year report	21 Jul 2026
Investors' Day	10 Sep 2026

### Analysts

Alexandre Müller  
Samuel Brandner

contact@researchdynamics.ch

Tel: +41 43 268 3232

[www.researchdynamics.ch](http://www.researchdynamics.ch)

## Continued Growth Amid Strategic Expansion

### Sales growth driven by acquisitions

The CPH Group (CPH) reported net sales of CHF 334.1 mn, corresponding to a 3.3% increase year-on-year (YoY). This growth was driven primarily by acquisitions (+8.1%), while currency effects (-3.8%) and organic factors (-1.0%) were a drag. EBITDA for the group amounted to CHF 50.3 mn, a 6.5% decline YoY. The corresponding margin dropped to 15.0% (FY24: 16.6%). Group EBIT came in at CHF 32.8 mn, while the corresponding margin declined to 9.8% (FY24: 12.1%). The net result declined to CHF 23.4 mn compared to CHF 34.4 mn in FY24, impacted by the elimination of one-time financial and non-operating income that benefitted the prior-year figures and higher financial expenses due to acquisitions. Cash flow from operating activities amounted to CHF 34.1 mn (FY24: CHF 53.3 mn) and free cash flow declined by 53.1% to CHF 16.4 mn, primarily due to an increase in net working capital of CHF 8.4 mn.

### Segmental performance

**Zeochem:** Net sales decreased by 2.2% to CHF 114.7 mn (FY24: CHF 117.3 mn), impacted by lower raw material costs passed on to customers, particularly for lithium-based products. Despite the sales dip, EBITDA reached a new record of CHF 23.9 mn, marking a 4.5% increase YoY, with the corresponding margin expanding to 20.8% (FY24: 19.5%). This margin expansion was driven by growth in high-value products such as deuterated compounds and chromatography gels, supported by the acquisitions of Sorbchem India in 2024 and SiliCycle in 2025. EBIT amounted to CHF 15.1 mn, a 1.6% increase YoY, resulting in an EBIT margin of 13.2% (FY24: 12.7%).

**Perlen Packaging:** Net sales stood at CHF 219.4 mn, an increase of 6.5% YoY, driven by the acquisition of LOG Pharma. Adjusted for currency and acquisitions, sales declined by 1.5% due to lower raw material prices and a shift in product mix towards monoblisters. The division faced headwinds from temporary overcapacities, which generated volume and price pressure and a sluggish economic environment in Europe. EBITDA declined by 22.2% to CHF 25.9 mn with a corresponding margin of 11.8% (FY24: 16.1%). The decline was attributed to tariffs, exchange rate effects, and a slightly higher cost base following the paper division spin-off. EBIT decreased by 35.7% to CHF 17.1 mn, with the corresponding margin compressing to 7.8% (FY24: 12.9%).

### Outlook for FY2026

The global economic landscape for 2026 remains characterized by volatility and geopolitical uncertainties, which continue to influence customer behaviour. While trade tariffs and regional conflicts present ongoing headwinds, CPH Group remains confident in the structural resilience of its end markets. The long-term global megatrends of health & demography and energy, which serve as the group's primary value drivers, remain fully intact. CPH Group anticipates a positive trend in demand and net sales as it leverages its expanded global footprint and stronger portfolio in high-value specialties.

**Group:** CPH Group expects to return to a trajectory of profitable growth in 2026. Management forecasts that sales, EBITDA, EBIT, and net result will all exceed the figures reported in 2025. The group's strategic focus will be on the integration of recent acquisitions and the rigorous exploitation of synergies, particularly within the pharmaceutical packaging segment.

**Zeochem:** In the Zeochem division, management expects both net sales and EBITDA to come in above the previous year's levels. A key operational priority will be the complete integration of SiliCycle, which was acquired in July 2025. This acquisition significantly strengthens Zeochem's position in the high-value chromatography gels market and complements its existing portfolio of molecular sieves and deuterated products. The division will continue to focus on advancing its strategy in specialized applications across global niche markets.

**Perlen Packaging:** For Perlen Packaging, CPH also projects sales and EBITDA to exceed 2025 levels. The division will focus on the completion of the integration of LOG Pharma, acquired in early 2025, to fully leverage the expanded product range comprising films, vials, and containers. In response to the margin pressures seen in 2025, the division has initiated a cost reduction program and further process optimizations, which are expected to support

profitability in 2026. The recovery in volumes, supported by the normalization of customer inventories, is anticipated to further drive growth.

**Mid-term Outlook:**

CPH has reaffirmed its mid-term financial targets, which support its strategy of expanding its geographic and product footprints and augmenting its product mix. The company expects annual net sales growth of 5-8%, an EBITDA margin of 16-18%, and a free cash flow margin of 8-10% (before acquisitions). The company aims to maintain an equity ratio of over 50% and a dividend payout ratio of 25-50%.

**Valuation and conclusion**

The reaffirmation of mid-term financial targets supports the long-term investment case, while the integration of strategic acquisitions should drive a recovery in earnings. Both Chemistry and Packaging division benefit from strong structural trends in health and energy, providing a resilient outlook despite market volatility. Furthermore, the realization of synergies from recent M&A and active cost management programs are expected to support margin expansion, moving back EBITDA margin in the 16–18% target range. This structural progress positions the group for renewed profitable growth.

We value CPH using DCF and relative valuation techniques. Factoring in the guidance, our intrinsic value stands at CHF 87.4 per share implying an upside of 35.3% from current levels. For relative valuation, since the Group operates in two entirely different divisions, we compare CPH's divisions with various sets of relevant industry peers. We have employed three parameters – EV/EBITDA, P/S, and P/E – to analyse the relative valuation of the Group. CPH currently trades at an EV/EBITDA multiple of 8.2x (FY2026e), a 1.2% premium to the weighted average multiple of division peers.

**Exhibit 1: CPH – Comparison with division peers**

Company	EV/EBITDA			P/S			P/E		
	3 year average	CY2026E	CY2027E	3 year average	CY2026E	CY2027E	3 year average	CY2026E	CY2027E
CPH Chemie & Paper	5.0x	8.2x	7.6x	0.9x	1.2x	1.1x	7.4x	16.6x	14.3x
<b>Chemistry peers:</b>									
Honeywell International	17.9x	18.3x	18.6x	3.7x	4.0x	4.1x	25.5x	24.9x	25.1x
EMS Chemie	25.2x	24.1x	23.2x	7.0x	7.1x	7.5x	32.2x	32.5x	30.9x
Arkema	5.6x	4.6x	5.7x	0.6x	0.5x	0.5x	14.6x	7.1x	13.3x
Clariant AG	7.8x	6.4x	6.5x	0.9x	0.6x	0.7x	57.9x	9.5x	11.3x
<b>Packaging peers:</b>									
West Pharmaceutical Services	28.3x	23.5x	21.7x	8.0x	6.0x	5.7x	44.7x	36.5x	34.0x
Amcor Plc	8.7x	19.0x	17.1x	1.0x	1.7x	1.6x	19.4x	14.4x	14.0x
Berry Global Group	7.4x	7.0x	6.5x	0.6x	0.6x	0.6x	11.1x	8.9x	7.9x
DS Smith	6.6x	6.9x	6.3x	0.7x	1.2x	1.1x	13.1x	17.2x	16.5x
Gerresheimer AG	10.3x	6.6x	6.7x	1.4x	0.3x	0.3x	30.2x	4.5x	9.3x
Macfarlane Group	6.1x	4.7x	5.7x	0.6x	0.4x	0.4x	12.0x	6.6x	10.5x
Median	9.0x	8.1x	7.8x	1.1x	1.2x	1.1x	18.8x	12.8x	13.6x
High	28.3x	24.1x	23.2x	8.0x	7.1x	7.5x	57.9x	36.5x	34.0x
Low	5.6x	4.6x	5.7x	0.6x	0.3x	0.3x	11.1x	4.5x	7.9x
Premium (disc) to peers	(44.2%)	1.2%	(2.3%)	(16.9%)	(1.9%)	(3.4%)	(60.8%)	29.8%	5.2%

Source: Refinitiv (as on 20 February 2026)

**Exhibit 2: CPH – Comparison with a weighted average of division peers**

	EV/EBITDA			P/S			P/E		
	3 year average	CY2026E	CY2027E	3 year average	CY2026E	CY2027E	3 year average	CY2026E	CY2027E
Chemistry peers	12.8x	12.4x	12.6x	2.3x	2.3x	2.4x	28.8x	17.2x	19.2x
Packaging peers	7.0x	6.8x	6.4x	0.6x	0.5x	0.5x	12.5x	7.8x	9.9x

Source: Refinitiv (as on 20 February 2026)

## DETAILED FINANCIAL STATEMENTS

### Income Statement

CHF mn (except per share)	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Zeochem	95	110	124	117	115	120	124
Paper	231	384	262				
Perlen Packaging	171	231	237	206	219	229	241
<b>Net Sales</b>	<b>497</b>	<b>725</b>	<b>362</b>	<b>323</b>	<b>334</b>	<b>349</b>	<b>365</b>
Cost of Sales	(336)	(431)	(203)	(174)	(171)	(178)	(185)
<b>Gross profit</b>	<b>161</b>	<b>294</b>	<b>158</b>	<b>149</b>	<b>163</b>	<b>171</b>	<b>180</b>
Personnel cost	(92)	(102)	(66)	(67)	(80)	(82)	(85)
Outsourced maintenance/repairs	(18)	(28)	(9)	(8)	0	(7)	(7)
Other operating expense	(25)	(34)	(19)	(20)	(33)	(28)	(29)
<b>Total operating costs</b>	<b>(135)</b>	<b>(163)</b>	<b>(94)</b>	<b>(96)</b>	<b>(112)</b>	<b>(117)</b>	<b>(122)</b>
<b>EBITDA</b>	<b>26</b>	<b>131</b>	<b>65</b>	<b>54</b>	<b>50</b>	<b>54</b>	<b>58</b>
Depreciation	(27)	(16)	(12)	(13)	(15)	(15)	(16)
Amortization	(1)	(2)	(1)	(2)	(2)	(2)	(2)
<b>Operating profit (EBIT) before impairment</b>	<b>(3)</b>	<b>112</b>	<b>52</b>	<b>39</b>	<b>33</b>	<b>36</b>	<b>40</b>
Impairment	(150)	0	0	0	0	0	0
<b>Operating profit (EBIT)</b>	<b>(153)</b>	<b>112</b>	<b>52</b>	<b>39</b>	<b>33</b>	<b>36</b>	<b>40</b>
Finance costs	(5)	(4)	(2)	0	(3)	(3)	(2)
Finance income	1	0	0	0	0	0	0
<b>Total financial inc/ (exp)</b>	<b>(4)</b>	<b>(4)</b>	<b>(2)</b>	<b>0</b>	<b>(3)</b>	<b>(3)</b>	<b>(2)</b>
<b>Profit before taxes</b>	<b>(157)</b>	<b>108</b>	<b>50</b>	<b>40</b>	<b>30</b>	<b>34</b>	<b>38</b>
Non-operating items	7	(8)	8	0	(0)	0	0
Income taxes	(2)	1	(12)	(7)	(6)	(7)	(8)
<b>Profit attributable to the parent</b>	<b>(152)</b>	<b>101</b>	<b>45</b>	<b>34</b>	<b>23</b>	<b>27</b>	<b>30</b>
<b>Basic EPS</b>	<b>(25.3)</b>	<b>16.8</b>	<b>7.5</b>	<b>5.7</b>	<b>3.9</b>	<b>4.5</b>	<b>5.0</b>
<b>Diluted EPS</b>	<b>(25.3)</b>	<b>16.8</b>	<b>7.5</b>	<b>5.7</b>	<b>3.9</b>	<b>4.5</b>	<b>5.0</b>
<b>DPS</b>	<b>1.3</b>	<b>4.5</b>	<b>4.0</b>	<b>2.0</b>	<b>2.0</b>	<b>2.5</b>	<b>2.5</b>

Source: Research Dynamics, Company data

### Balance Sheet

CHF mn	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Assets</b>							
<b>Non-current assets</b>							
PPE	196.5	213.7	116.3	128.8	154.3	154.2	154.2
Intangible assets	5.8	4.5	2.6	6.3	8.3	7.0	6.0
Long-term financial assets	10.0	10.0	27.2	27.8	28.9	28.9	28.9
Long-term financial receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other non-current assets	58.4	55.8	0.0	0.0	0.0	0.0	0.0
<b>Total non-current assets</b>	<b>270.7</b>	<b>284.0</b>	<b>146.1</b>	<b>163.0</b>	<b>191.5</b>	<b>190.1</b>	<b>189.1</b>
<b>Current assets</b>							
Inventories	87.5	113.1	72.5	74.8	80.1	81.8	85.2
Trade accounts receivable	69.3	93.9	51.1	48.3	56.5	59.3	62.0
Other receivables	28.5	21.9	18.5	9.7	8.7	8.7	8.7
Prepaid exp and accrued income	9.2	9.6	4.4	5.2	5.1	5.1	5.1
Short-term financial receivables	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Liquid funds and Securities	95.1	143.6	35.4	31.6	27.0	27.0	27.1
<b>Total assets</b>	<b>560.4</b>	<b>666.2</b>	<b>327.9</b>	<b>332.6</b>	<b>368.9</b>	<b>371.8</b>	<b>377.1</b>
<b>Shareholders' Equity and Liabilities</b>							
Share capital	1.2	1.2	0.9	0.9	0.9	0.9	0.9
Capital reserves	(0.1)	(0.1)	(0.5)	(0.5)	(0.4)	(0.4)	(0.4)
Profit reserves	459.5	397.1	216.3	209.0	203.0	188.0	200.0
Net result for the year	(151.6)	0.0	0.0	0.0	0.0	27.0	30.3
<b>Non-current liabilities</b>							
Long-term financial liabilities	106.6	0.0	0.0	8.0	10.1	10.1	10.1
Pension scheme liabilities	1.4	1.7	0.0	0.0	0.0	0.0	0.0
Other long-term liabilities	0.3	0.0	0.0	0.0	2.4	2.4	2.4
Long-term provisions	24.1	31.4	32.3	33.8	37.3	37.3	37.3
<b>Current liabilities</b>							
Trade accounts payable	84.8	93.0	34.1	34.1	33.7	34.1	35.0
Other payables	3.9	6.5	2.4	2.4	4.5	4.5	4.5
Accrued liabilities and deferred income	18.3	27.2	31.4	31.4	30.2	30.2	30.2
Short-term financial liabilities	3.2	98.9	11.0	11.0	43.2	33.7	22.7
Short-term provisions	7.4	7.8	2.6	2.6	3.7	3.7	3.7
<b>Total liabilities</b>	<b>249.9</b>	<b>266.6</b>	<b>113.7</b>	<b>123.2</b>	<b>165.0</b>	<b>155.9</b>	<b>145.8</b>
<b>Total equity and liab.</b>	<b>560.4</b>	<b>666.2</b>	<b>327.9</b>	<b>332.6</b>	<b>368.9</b>	<b>371.8</b>	<b>377.1</b>

Source: Research Dynamics, Company data

### Cash Flow Statement

CHF mn	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Net profit for the period	(151.4)	101.0	45.1	34.4	23.4	27.1	30.3
Non-cash adjustments:	169.5	28.4	9.6	8.1	19.2	17.6	18.2
<b>Change in CA and CL:</b>							
(Increase)/ decrease in inventories	(9.6)	(27.2)	3.3	(0.4)	(2.3)	(1.7)	(3.4)
Decrease in trade accounts receivable	(15.5)	(26.7)	3.6	6.0	(1.7)	(2.8)	(2.7)
Increase/ (decrease) in trade accounts payable	30.7	6.9	(12.0)	(1.7)	(3.2)	0.4	1.0
Other changes in working capital	(7.9)	15.3	8.2	6.9	(1.3)	0.0	0.0
<b>CFO</b>	<b>15.8</b>	<b>97.6</b>	<b>57.9</b>	<b>53.3</b>	<b>34.1</b>	<b>40.6</b>	<b>43.3</b>
Investments in tangible fixed assets	(23.0)	(32.9)	(17.4)	(19.8)	(18.9)	(15.1)	(15.9)
Disposals of tangible fixed assets	5.2	4.3	14.8	2.0	3.5	0.0	0.0
Investments in intangible assets	(1.6)	(1.0)	(0.4)	(0.6)	(2.4)	(1.1)	(1.3)
Sale of subsidiary/ Divestiture of interests	0.2	0.0	0.0	(32.8)	(33.2)	0.0	0.0
Investments in business activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Repayment of long-term financial receivables	(0.1)	0.0	(2.4)	0.0	0.0	0.0	0.0
<b>CFI</b>	<b>(19.2)</b>	<b>(29.6)</b>	<b>(5.5)</b>	<b>(51.3)</b>	<b>(50.9)</b>	<b>(16.2)</b>	<b>(17.2)</b>
Increase/ (Decrease) in short-term financial liabilities and receivables	(6.9)	(3.2)	4.6	10.2	25.1	(9.5)	(11.0)
Increase/ (Decrease) in long-term financial liabilities	0.0	(6.5)	(98.7)	7.9	0.7	0.0	0.0
Increase in other long-term liabilities	(0.3)	(1.3)	0.0	0.0	0.0	0.0	0.0
Dividends to shareholders	(10.8)	(7.8)	(27.0)	(24.0)	(12.0)	(15.0)	(15.0)
<b>CFF</b>	<b>(18.0)</b>	<b>(19.0)</b>	<b>(121.7)</b>	<b>(6.4)</b>	<b>13.5</b>	<b>(24.5)</b>	<b>(26.0)</b>
Exchange (losses)/gains	0.2	(0.5)	(2.1)	0.5	(1.3)	0.0	0.0
<b>Net change in cash</b>	<b>(21.2)</b>	<b>48.5</b>	<b>(71.4)</b>	<b>(3.8)</b>	<b>(4.6)</b>	<b>(0.1)</b>	<b>0.1</b>
Opening cash balance	116.3	95.1	106.8	35.4	31.6	27.0	27.0
<b>Closing cash balance</b>	<b>95.1</b>	<b>143.6</b>	<b>35.4</b>	<b>31.6</b>	<b>27.0</b>	<b>27.0</b>	<b>27.1</b>

### Key Ratios

	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Growth Ratios</b>							
Sales Growth	12%	46%	(14%)	(11%)	3%	4%	5%
Chemistry division	30%	16%	13%	(6%)	(2%)	5%	3%
Paper division	10%	67%	(32%)	(17%)	(17%)	9%	9%
Packaging division	5%	35%	3%	(13%)	7%	4%	6%
Operating Profit Growth	NM	NM	(54%)	(25%)	(16%)	11%	10%
Net Income Growth	NM	NM	(55%)	NM	(32%)	16%	12%
<b>Profitability Ratios (%)</b>							
Operating margin (%)	(1%)	16%	14%	12%	10%	10%	11%
Chemistry division	16%	13%	13%	13%	13%	14%	14%
Paper division	(11%)	20%	12%	(7%)	(7%)	9%	9%
Packaging division	3%	10%	15%	13%	8%	9%	9%
EBITDA Margin %	5%	18%	18%	17%	15%	15%	16%
Net Margin (%)	(31%)	14%	12%	11%	7%	8%	8%
<b>Return Ratios</b>							
Profit Margin	(31%)	14%	12%	11%	7%	8%	8%
Asset Turnover	0.8x	1.2x	0.6x	0.7x	1.0x	0.9x	1.0x
Financial Leverage	1.6x	1.7x	1.5x	1.4x	1.7x	1.8x	1.7x
Dupont ROE (%)	(39%)	28%	11%	11%	11%	13%	14%
ROCE (%)	(1%)	28%	12%	18%	15%	16%	17%
ROA (%)	(24%)	16%	7%	7%	7%	7%	8%
<b>Leverage Ratios</b>							
Debt - Equity Ratio	0.4x	0.2x	0.0x	0.1x	0.3x	0.2x	0.1x
Net Debt - Equity Ratio	0.0x	(0.1x)	(0.2x)	(0.1x)	0.1x	0.1x	0.0x
Interest Coverage	(1.1x)	46.8x	19.9x	7.7x	16.1x	14.4x	17.6x
<b>Liquidity Ratios</b>							
Current Ratio	2.5x	1.6x	2.5x	2.1x	1.5x	1.7x	2.0x
Quick Ratio	1.7x	1.2x	1.7x	1.2x	0.8x	0.9x	1.1x
<b>Valuation Ratios</b>							
EV/EBITDA	16.0x	3.1x	6.3x	7.6x	8.2x	7.6x	7.0x
P/E	nm	3.8x	8.5x	11.1x	16.6x	14.3x	12.8x

Source: Research Dynamics, Bloomberg, Company data

**DISCLAIMER**

CPH Group AG ("CPH") is a client of Research Dynamics. The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. Research Dynamics is a division of Dynamics Group AG. Dynamics Group is an independent consultancy firm focused on strategic advisory, communication management and research and analysis.

This report (henceforth known as "document") has been drafted by the authors concerned as a non-binding opinion on the market situation and on the instruments of investment in question and compiled by Dynamics Group in order to provide background information about the companies. It is intended exclusively for the purpose of information.

Dynamics Group has not individually verified the information and data on which this document is based. All information and data in this document originate from generally available sources which the author concerned or Dynamics Group viewed as reliable at the time of drafting this document. However, no liability can be assumed for their correctness, accuracy, completeness and appropriateness – neither expressly nor tacitly. The contents of this document do not represent an assurance or guarantee by the authors concerned or Dynamics Group. Forward-looking information or statements in this document contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations

Dynamics Group shall not be liable for any consequential damage to properties – on whatever legal grounds it may be. Liability of Dynamics Group on account of premeditation or gross negligence shall remain unaffected by this.

Dynamics Group has no permission to provide assurances or assume guarantees on behalf of the companies or a third party mentioned in this document. Neither the companies mentioned in this document nor any other individual assumes liability for any loss, damage or detriment that may result from the use of this document, especially when taking decisions on investments, or from other reasons. Dynamics Group cannot be held responsible for detrimental consequences that occur or may occur due to the use or its omission based on the views and inferences contained in this document. Past performance trends of value, price or rates do not provide any indications to the future trends for an investment. Dynamics Group does not provide any guarantees for the suggested yield or the achievement of referred targets.

This document does neither represent an offer of purchase, holding or sale of any securities, money market instruments or of derivatives, nor does it contain the basis for a contract or a commitment of any kind. Every investment, for example, in debentures, shares and options, is associated with enormous risks. A decision on investment with regard to any security may not be based on this document. This document is neither an advice on investment, nor a recommendation or invitation for purchasing, holding or selling any securities, money market instruments or derivatives.

Dynamics Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this document. However, the respective directors, employees and contractors of Dynamics Group may hold positions in the described securities and/or options, futures and other derivatives that are based on these securities.

This document has been provided to you for information only. It may not be reproduced or distributed to others or published in any other form partially or fully.

The distribution of this document and the information contained therein may be restricted in other jurisdictions by law and persons who may come into possession of this document must be aware of possible restrictions and adhere to the same. Failure to comply with such restrictions may constitute an infringement of the laws in USA or Canada governing the securities or of the laws of any other jurisdiction.

This study is protected by the copyright laws. It may be used only for the purpose as defined in this disclaimer. Portions of the study, if quoted, must be acknowledged by indicating the source. Any use other than this shall require prior written permission by Dynamics Group. Reproduction, circulation, publication and provision of online access to the document shall be regarded as its use and the same shall require permission. Circulation of this document, especially in a foreign country, may be permitted only under the provisions of the disclaimer and the applicable regulations. Unauthorized use of the study or omission of details of the source or the acknowledgement of copyright may lead to initiation of a civil suit for damages and be liable for prosecution.

If any part or individual formulations of this disclaimer are found to be unsustainable or become unsustainable at a future date, the rest of the contents and their validity shall not be affected by it.

**Dynamics Group AG**

Utoquai 43  
CH-8008 Zürich  
Tel. +41 43 268 32 32  
Fax +41 43 268 32 39

Zeughausgasse 22  
CH-3011 Bern  
Tel. +41 31 312 28 41  
Fax +41 31 312 28 49

21, rue des Caroubiers  
CH-1227 Carouge/GE  
Tel. +41 22 308 62 20  
Fax +41 22 308 62 36

[contact@dynamicsgroup.ch](mailto:contact@dynamicsgroup.ch)

[www.dynamicsgroup.ch](http://www.dynamicsgroup.ch)